BRAF V600E

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Melanoma2
BRAF V600E OR BRAF V600K	Dabrafenib + TrametinibCombination	Predictive	B	Supports Sensitivity Response	3	accepted	EID93 This was a Phase I and II study (NCT01072175) of dabrafenib and trametinib combination therapy vs. dabrafenib monotherapy in patients with metastatic melanoma. Cutaneous squamous-cell carcinoma was… (full text at CIViC) PMID 23020132 · Flaherty et al., 2012 · Open in CIViC	civic
BRAF V600E OR BRAF V600K	Vemurafenib	Predictive	B	Supports Sensitivity Response	3	accepted	EID1410 Phase 2 trial in 132 patients with previously treated metastatic melanoma with BRAF V600E (n=122) or V600K (n=10) mutation. Confirmed overall response rate was 53% (95% confidence interval [CI], 44 t… (full text at CIViC) PMID 22356324 · Sosman et al., 2012 ·

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Melanoma2

BRAF V600E OR BRAF V600K

Dabrafenib + TrametinibCombination

Predictive

Supports Sensitivity Response

accepted

EID93

This was a Phase I and II study (NCT01072175) of dabrafenib and trametinib combination therapy vs. dabrafenib monotherapy in patients with metastatic melanoma. Cutaneous squamous-cell carcinoma was… (full text at CIViC)

PMID 23020132 · Flaherty et al., 2012 · Open in CIViC

civic

BRAF V600E OR BRAF V600K

Vemurafenib

Predictive

Supports Sensitivity Response

accepted

EID1410

Phase 2 trial in 132 patients with previously treated metastatic melanoma with BRAF V600E (n=122) or V600K (n=10) mutation. Confirmed overall response rate was 53% (95% confidence interval [CI], 44 t… (full text at CIViC)

PMID 22356324 · Sosman et al., 2012 ·

Multiple Myeloma3
BRAF V600E	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID463 In patients with multiple myeloma, those with BRAF V600E had shorter overall survival than wild-type. PMID 23612012 · Andrulis et al., 2013 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	3	accepted	EID1698 A 65-year-old man presented with stage II myeloma. He was initially treated with chemotherapy and he received an autologous stem cell transplant. Sequencing of the recurrent tumor harbored BRAF V600E… (full text at CIViC) PMID 24997557 · Sharman et al., 2014 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	2	accepted	EID1699 A 54-year-old man presented with stage II myeloma. He was initially treated with chemotherapy and received an autologous stem cell transplant. Genomic profiling of the bone biopsy revealed BRAF V600… (full text at CIViC) PMID 24997557 · Sharman et al., 2014 · Open in CIViC	civic

Multiple Myeloma3

BRAF V600E

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID463

In patients with multiple myeloma, those with BRAF V600E had shorter overall survival than wild-type.

PMID 23612012 · Andrulis et al., 2013 · Open in CIViC

civic

BRAF V600E

Vemurafenib

Predictive

Supports Sensitivity Response

accepted

EID1698

A 65-year-old man presented with stage II myeloma. He was initially treated with chemotherapy and he received an autologous stem cell transplant. Sequencing of the recurrent tumor harbored BRAF V600E… (full text at CIViC)

PMID 24997557 · Sharman et al., 2014 · Open in CIViC

civic

BRAF V600E

Vemurafenib

Predictive

Supports Sensitivity Response

accepted

EID1699

A 54-year-old man presented with stage II myeloma. He was initially treated with chemotherapy and received an autologous stem cell transplant. Genomic profiling of the bone biopsy revealed BRAF V600… (full text at CIViC)

PMID 24997557 · Sharman et al., 2014 · Open in CIViC

civic

Ovarian Carcinoma1
BRAF V600E AND BRAF Amplification	Atezolizumab + BevacizumabCombination	Predictive	B	Supports Sensitivity Response	1	submitted	EID9885 AURELIA trial indicated substantial improvement in progression-free survival and overall survival in ovarian cancer patients with PD-L1 positive expression in response to bevacizumab plus single regim… (full text at CIViC) PMID 31105696 · Zhang et al., 2019 · Open in CIViC	civic

Ovarian Carcinoma1

BRAF V600E AND BRAF Amplification

Atezolizumab + BevacizumabCombination

Predictive

Supports Sensitivity Response

submitted

EID9885

AURELIA trial indicated substantial improvement in progression-free survival and overall survival in ovarian cancer patients with PD-L1 positive expression in response to bevacizumab plus single regim… (full text at CIViC)

PMID 31105696 · Zhang et al., 2019 · Open in CIViC

civic

Ovarian Serous Adenocarcinoma1
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	3	accepted	EID3787 A stage 4B, low-grade papillary serous ovarian adenocarcinoma patient, harboring a BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was treated with standard ch… (full text at CIViC) PMID 26490654 · Combe et al., 2015 · Open in CIViC	civic

Ovarian Serous Adenocarcinoma1

BRAF V600E

Vemurafenib

Predictive

Supports Sensitivity Response

accepted

EID3787

A stage 4B, low-grade papillary serous ovarian adenocarcinoma patient, harboring a BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was treated with standard ch… (full text at CIViC)

PMID 26490654 · Combe et al., 2015 · Open in CIViC

civic

Pancreatic Adenocarcinoma1
BRAF V600E	Dabrafenib/Trametinib Regimen	Predictive	C	Supports Sensitivity Response	2	submitted	EID12811 A 78-year-old Chinese female patient presented with BRAF V600E-mutant metastatic pancreatic adenocarcinoma. The patient received two cycles of chemotherapy. Following the second incomplete cycle of ch… (full text at CIViC) PMID 41367868 · Liu et al., 2025 · Open in CIViC	civic

Pancreatic Adenocarcinoma1

BRAF V600E

Dabrafenib/Trametinib Regimen

Predictive

Supports Sensitivity Response

submitted

EID12811

A 78-year-old Chinese female patient presented with BRAF V600E-mutant metastatic pancreatic adenocarcinoma. The patient received two cycles of chemotherapy. Following the second incomplete cycle of ch… (full text at CIViC)

PMID 41367868 · Liu et al., 2025 · Open in CIViC

civic

Pilocytic Astrocytoma3
BRAF V600E	Dabrafenib + TrametinibCombination	Predictive	A	Supports Sensitivity Response	1	submitted	EID11313 This study is part of an ongoing open-label, single-arm, phase 2 Rare Oncology Agnostic Research (ROAR) basket trial enlisting 45 patients (31 with glioblastoma) into the high-grade glioma cohort (oth… (full text at CIViC) PMID 34838156 · Wen et al., 2022 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	—	submitted	EID3772 A pediatric pilocytic astrocytoma patient harboring BRAF V600E mutation, BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was treated with standard chemotherapy… (full text at CIViC) PMID 24821190 · Skrypek et al., 2014 · Open in CIViC	civic
BRAF V600E OR KIAA1549::BRAF Fusion	Selumetinib	Predictive	B	Supports Sensitivity Response	3	submitted	EID11316 In this phase II trial on patients with pediatric low-grade glioma were assigned to six unique strata according to histology, tumour location, NF1 status, and BRAF aberration status. This study report… (full text at CIViC) PMID 31151904 · Fangusaro et al., 2019 · Open in CIViC	civic

Pilocytic Astrocytoma3

BRAF V600E

Dabrafenib + TrametinibCombination

Predictive

Supports Sensitivity Response

submitted

EID11313

This study is part of an ongoing open-label, single-arm, phase 2 Rare Oncology Agnostic Research (ROAR) basket trial enlisting 45 patients (31 with glioblastoma) into the high-grade glioma cohort (oth… (full text at CIViC)

PMID 34838156 · Wen et al., 2022 · Open in CIViC

civic

BRAF V600E

Vemurafenib

Predictive

Supports Sensitivity Response

—

submitted

EID3772

A pediatric pilocytic astrocytoma patient harboring BRAF V600E mutation, BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was treated with standard chemotherapy… (full text at CIViC)

PMID 24821190 · Skrypek et al., 2014 · Open in CIViC

civic

BRAF V600E OR KIAA1549::BRAF Fusion

Selumetinib

Predictive

Supports Sensitivity Response

submitted

EID11316

In this phase II trial on patients with pediatric low-grade glioma were assigned to six unique strata according to histology, tumour location, NF1 status, and BRAF aberration status. This study report… (full text at CIViC)

PMID 31151904 · Fangusaro et al., 2019 · Open in CIViC

civic

Pleomorphic Xanthoastrocytoma3
BRAF V600E	Dabrafenib + TrametinibCombination	Predictive	A	Supports Sensitivity Response	1	submitted	EID11312 This study is part of an ongoing open-label, single-arm, phase 2 Rare Oncology Agnostic Research (ROAR) basket trial enlisting 45 patients (31 with glioblastoma) into the high-grade glioma cohort (oth… (full text at CIViC) PMID 34838156 · Wen et al., 2022 · Open in CIViC	civic
BRAF V600E	Dabrafenib + TrametinibCombination	Predictive	C	Supports Sensitivity Response	2	submitted	EID11311 In this case series, two patients with BRAF V600E mutant pleomorphic xanthoastrocytoma were treated using the BRAF inhibitor dabrafenib and trametinib in combination with the MEK inhibitor trametinib.… (full text at CIViC) PMID 28984141 · Brown et al., 2017 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	—	submitted	EID3786 An anaplastic pleomorphic xanthoastrocytoma patient harboring BRAF V600E mutation was associated with improved response to vemurafenib treatment. The patient was treated with radiation and temozolomid… (full text at CIViC) PMID 25092772 · Lee et al., 2016 · Open in CIViC	civic

Pleomorphic Xanthoastrocytoma3

BRAF V600E

Dabrafenib + TrametinibCombination

Predictive

Supports Sensitivity Response

submitted

EID11312

PMID 34838156 · Wen et al., 2022 · Open in CIViC

civic

BRAF V600E

Dabrafenib + TrametinibCombination

Predictive

Supports Sensitivity Response

submitted

EID11311

In this case series, two patients with BRAF V600E mutant pleomorphic xanthoastrocytoma were treated using the BRAF inhibitor dabrafenib and trametinib in combination with the MEK inhibitor trametinib.… (full text at CIViC)

PMID 28984141 · Brown et al., 2017 · Open in CIViC

civic

BRAF V600E

Vemurafenib

Predictive

Supports Sensitivity Response

—

submitted

EID3786

An anaplastic pleomorphic xanthoastrocytoma patient harboring BRAF V600E mutation was associated with improved response to vemurafenib treatment. The patient was treated with radiation and temozolomid… (full text at CIViC)

PMID 25092772 · Lee et al., 2016 · Open in CIViC

civic

Solid Neoplasm1
BRAF V600E	Dabrafenib + TrametinibCombination	Predictive	A	Supports Sensitivity Response	4	accepted	EID12161 In this trial, patients with advanced rare tumours harbouring BRAF V600E mutations were treated with a combination of dabrafenib and trametinib. The study included eight distinct cohorts: anaplastic t… (full text at CIViC) PMID 37059834 · Subbiah et al., 2023 · Open in CIViC	civic

Solid Neoplasm1

BRAF V600E

Dabrafenib + TrametinibCombination

Predictive

Supports Sensitivity Response

accepted

EID12161

In this trial, patients with advanced rare tumours harbouring BRAF V600E mutations were treated with a combination of dabrafenib and trametinib. The study included eight distinct cohorts: anaplastic t… (full text at CIViC)

PMID 37059834 · Subbiah et al., 2023 · Open in CIViC

civic

Thyroid Gland Anaplastic Carcinoma18
BRAF V600E	(oncogenic)	Oncogenic	B	Supports Oncogenicity	3	submitted	EID13014 A systematic review and meta-analysis of 34 studies comprising 978 patients with anaplastic thyroid carcinoma (ATC) reported a pooled prevalence of BRAF V600E of 33% (95% CI, 26%–40%). When cases with… (full text at CIViC) PMID 39086414 · Behnagh et al., 2024 · Open in CIViC	civic
BRAF V600E	(oncogenic)	Oncogenic	B	Supports Oncogenicity	3	submitted	EID13015 Targeted next-generation sequencing of 11 anaplastic thyroid carcinomas (ATCs) with matched normal tissue identified BRAF V600E in 10 of 11 tumors (91%), making BRAF the most frequently mutated gene i… (full text at CIViC) PMID 26980298 · Jeon et al., 2016 · Open in CIViC	civic
BRAF V600E	(oncogenic)	Oncogenic	B	Supports Oncogenicity	3	rejected	EID13016 Comprehensive genomic profiling of 68 anaplastic thyroid carcinomas (ATCs) identified BRAF alterations in 10.3% of tumors. BRAF mutations were more common in ATCs with a concurrent or prior papillary … (full text at CIViC) PMID 40674659 · Trivedi et al., 2025 · Open in CIViC	civic
BRAF V600E	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID13011 In BRAF V600E-positive murine anaplastic thyroid carcinoma (ATC) cell lines (TBP-3743, TBPt-3403, and TBPt-3610R), treatment with the BRAF inhibitor PLX4720 decreased ERK phosphorylation and significa… (full text at CIViC) PMID 24994118 · Vanden Borre et al., 2014 · Open in CIViC	civic
BRAF V600E	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID13012 In an orthotopic mouse model generated using BRAF V600E-positive 8505c anaplastic thyroid carcinoma cells, treatment with the selective BRAF V600E inhibitor PLX4720 decreased phospho-ERK1/2 expression… (full text at CIViC) PMID 22202162 · Nehs et al., 2012 · Open in CIViC	civic
BRAF V600E	Dabrafenib + TrametinibCombination	Predictive	B	Supports Sensitivity Response	4	accepted	EID6975 Interim analysis of a basket trial evaluating the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in previously treated V600E-mutated patients showed 11/16 patients with anap… (full text at CIViC) PMID 29072975 · Subbiah et al., 2018 · Open in CIViC	civic
BRAF V600E	Dabrafenib + TrametinibCombination	Predictive	B	Supports Sensitivity Response	3	submitted	EID12957 In this retrospective, single-center, real-world study conducted between May 2018 and April 2022, 27 patients with anaplastic thyroid carcinoma (ATC) were stratified into three groups: patients with B… (full text at CIViC) PMID 36651156 · da Silva et al., 2023 · Open in CIViC	civic
BRAF V600E	Dabrafenib + TrametinibCombination	Predictive	B	Supports Sensitivity Response	3	submitted	EID12959 This multi-institutional retrospective study analyzed 44 patients with anaplastic thyroid carcinoma (ATC) treated across three hospitals in Taiwan. BRAF mutation testing was performed in 24 patients (… (full text at CIViC) PMID 36504909 · Chang et al., 2022 · Open in CIViC	civic
BRAF V600E	Dabrafenib + TrametinibCombination	Predictive	B	Supports Sensitivity Response	4	submitted	EID12960 In this systematic review and meta-analysis, the authors evaluated the predictive relevance of the BRAF V600E variant in patients with anaplastic thyroid carcinoma (ATC) treated with MAPK pathway-targ… (full text at CIViC) PMID 38709445 · Priantti et al., 2024 · Open in CIViC	civic
BRAF V600E	Dabrafenib + TrametinibCombination	Predictive	B	Supports Sensitivity Response	3	submitted	EID13282 In a single-center retrospective study of 6 patients with BRAF V600E-positive anaplastic thyroid carcinoma treated with dabrafenib plus trametinib, 4/6 patients (67%; 95% CI 24–94%) achieved an object… (full text at CIViC) PMID 40844731 · Ando et al., 2025 · Open in CIViC	civic
BRAF V600E	Dabrafenib + TrametinibCombination	Predictive	C	Supports Sensitivity Response	3	submitted	EID12956 A 47-year-old woman with advanced metastatic anaplastic thyroid carcinoma (ATC) harboring a BRAF V600E mutation, identified by comprehensive genomic profiling of a resected lung metastasis, received c… (full text at CIViC) PMID 27697975 · Agarwal et al., 2016 · Open in CIViC	civic
BRAF V600E	Dabrafenib + TrametinibCombination	Predictive	C	Supports Sensitivity Response	3	submitted	EID12958 This single-patient case report describes a 63-year-old woman diagnosed with BRAF V600E-mutated anaplastic thyroid carcinoma (ATC). Following multiple surgical resections, the patient developed recurr… (full text at CIViC) PMID 37900238 · Lee et al., 2023 · Open in CIViC	civic
BRAF V600E	Dabrafenib/Trametinib Regimen	Predictive	A	Supports Sensitivity Response	4	submitted	EID10785 An updated analysis of the phase 2 ROAR basket trial evaluating combination dabrafenib and trametinib in 36 BRAF V600E mutated anaplastic thyroid carcinoma patients (16 patients previously described i… (full text at CIViC) PMID 35026411 · Subbiah et al., 2022 · Open in CIViC	civic
BRAF V600E	Dabrafenib + Pembrolizumab + TrametinibCombination	Predictive	B	Supports Sensitivity Response	3	submitted	EID13283 In a retrospective single-center cohort of patients with BRAF V600E-mutated anaplastic thyroid carcinoma, 30 patients treated with upfront dabrafenib, trametinib, and pembrolizumab had a significantly… (full text at CIViC) PMID 38226606 · Hamidi et al., 2024 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	B	Supports Sensitivity Response	3	accepted	EID6045 In a phase 2 “basket” study of vemurafenib in BRAF V600-positive non-melanoma cancers, seven patients with anaplastic thyroid cancer were enrolled. All 7 patients had V600E mutations. One complete res… (full text at CIViC) PMID 26287849 · Hyman et al., 2015 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	3	submitted	EID3744 In an 80 year old female anaplastic thyroid cancer patient harboring BRAF V600E and TP53 E180K co-mutations, BRAF V600E was associated with response to vemurafenib treatment. Prior to identification o… (full text at CIViC) PMID 27532222 · Prager et al., 2016 · Open in CIViC	civic
BRAF V600E	Pertuzumab + VemurafenibCombination	Predictive	C	Supports Sensitivity Response	3	accepted	EID5961 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient … (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF V600E	Radiation Therapy + VemurafenibCombination	Predictive	C	Supports Sensitivity Response	3	submitted	EID3743 A 51 year old male anaplastic thyroid cancer patient harboring BRAF V600E experienced rapid improvement in response to vemurafenib. The patient was initially treated with paclitaxel and carboplatin bu… (full text at CIViC) PMID 23406047 · Rosove et al., 2013 · Open in CIViC	civic

Thyroid Gland Anaplastic Carcinoma18

BRAF V600E

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID13014

A systematic review and meta-analysis of 34 studies comprising 978 patients with anaplastic thyroid carcinoma (ATC) reported a pooled prevalence of BRAF V600E of 33% (95% CI, 26%–40%). When cases with… (full text at CIViC)

PMID 39086414 · Behnagh et al., 2024 · Open in CIViC

civic

BRAF V600E

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID13015

Targeted next-generation sequencing of 11 anaplastic thyroid carcinomas (ATCs) with matched normal tissue identified BRAF V600E in 10 of 11 tumors (91%), making BRAF the most frequently mutated gene i… (full text at CIViC)

PMID 26980298 · Jeon et al., 2016 · Open in CIViC

civic

BRAF V600E

(oncogenic)

Oncogenic

Supports Oncogenicity

rejected

EID13016

Comprehensive genomic profiling of 68 anaplastic thyroid carcinomas (ATCs) identified BRAF alterations in 10.3% of tumors. BRAF mutations were more common in ATCs with a concurrent or prior papillary … (full text at CIViC)

PMID 40674659 · Trivedi et al., 2025 · Open in CIViC

civic

BRAF V600E

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID13011

In BRAF V600E-positive murine anaplastic thyroid carcinoma (ATC) cell lines (TBP-3743, TBPt-3403, and TBPt-3610R), treatment with the BRAF inhibitor PLX4720 decreased ERK phosphorylation and significa… (full text at CIViC)

PMID 24994118 · Vanden Borre et al., 2014 · Open in CIViC

civic

BRAF V600E

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID13012

In an orthotopic mouse model generated using BRAF V600E-positive 8505c anaplastic thyroid carcinoma cells, treatment with the selective BRAF V600E inhibitor PLX4720 decreased phospho-ERK1/2 expression… (full text at CIViC)

PMID 22202162 · Nehs et al., 2012 · Open in CIViC

civic

BRAF V600E

Dabrafenib + TrametinibCombination

Predictive

Supports Sensitivity Response

accepted

EID6975

Interim analysis of a basket trial evaluating the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in previously treated V600E-mutated patients showed 11/16 patients with anap… (full text at CIViC)

PMID 29072975 · Subbiah et al., 2018 · Open in CIViC

civic

BRAF V600E

Dabrafenib + TrametinibCombination

Predictive

Supports Sensitivity Response

submitted

EID12957

In this retrospective, single-center, real-world study conducted between May 2018 and April 2022, 27 patients with anaplastic thyroid carcinoma (ATC) were stratified into three groups: patients with B… (full text at CIViC)

PMID 36651156 · da Silva et al., 2023 · Open in CIViC

civic

BRAF V600E

Dabrafenib + TrametinibCombination

Predictive

Supports Sensitivity Response

submitted

EID12959

This multi-institutional retrospective study analyzed 44 patients with anaplastic thyroid carcinoma (ATC) treated across three hospitals in Taiwan. BRAF mutation testing was performed in 24 patients (… (full text at CIViC)

PMID 36504909 · Chang et al., 2022 · Open in CIViC

civic

BRAF V600E

Dabrafenib + TrametinibCombination

Predictive

Supports Sensitivity Response

submitted

EID12960

In this systematic review and meta-analysis, the authors evaluated the predictive relevance of the BRAF V600E variant in patients with anaplastic thyroid carcinoma (ATC) treated with MAPK pathway-targ… (full text at CIViC)

PMID 38709445 · Priantti et al., 2024 · Open in CIViC

civic

BRAF V600E

Dabrafenib + TrametinibCombination

Predictive

Supports Sensitivity Response

submitted

EID13282

In a single-center retrospective study of 6 patients with BRAF V600E-positive anaplastic thyroid carcinoma treated with dabrafenib plus trametinib, 4/6 patients (67%; 95% CI 24–94%) achieved an object… (full text at CIViC)

PMID 40844731 · Ando et al., 2025 · Open in CIViC

civic

BRAF V600E

Dabrafenib + TrametinibCombination

Predictive

Supports Sensitivity Response

submitted

EID12956

A 47-year-old woman with advanced metastatic anaplastic thyroid carcinoma (ATC) harboring a BRAF V600E mutation, identified by comprehensive genomic profiling of a resected lung metastasis, received c… (full text at CIViC)

PMID 27697975 · Agarwal et al., 2016 · Open in CIViC

civic

BRAF V600E

Dabrafenib + TrametinibCombination

Predictive

Supports Sensitivity Response

submitted

EID12958

This single-patient case report describes a 63-year-old woman diagnosed with BRAF V600E-mutated anaplastic thyroid carcinoma (ATC). Following multiple surgical resections, the patient developed recurr… (full text at CIViC)

PMID 37900238 · Lee et al., 2023 · Open in CIViC

civic

BRAF V600E

Dabrafenib/Trametinib Regimen

Predictive

Supports Sensitivity Response

submitted

EID10785

An updated analysis of the phase 2 ROAR basket trial evaluating combination dabrafenib and trametinib in 36 BRAF V600E mutated anaplastic thyroid carcinoma patients (16 patients previously described i… (full text at CIViC)

PMID 35026411 · Subbiah et al., 2022 · Open in CIViC

civic

BRAF V600E

Dabrafenib + Pembrolizumab + TrametinibCombination

Predictive

Supports Sensitivity Response

submitted

EID13283

In a retrospective single-center cohort of patients with BRAF V600E-mutated anaplastic thyroid carcinoma, 30 patients treated with upfront dabrafenib, trametinib, and pembrolizumab had a significantly… (full text at CIViC)

PMID 38226606 · Hamidi et al., 2024 · Open in CIViC

civic

BRAF V600E

Vemurafenib

Predictive

Supports Sensitivity Response

accepted

EID6045

In a phase 2 “basket” study of vemurafenib in BRAF V600-positive non-melanoma cancers, seven patients with anaplastic thyroid cancer were enrolled. All 7 patients had V600E mutations. One complete res… (full text at CIViC)

PMID 26287849 · Hyman et al., 2015 · Open in CIViC

civic

BRAF V600E

Vemurafenib

Predictive

Supports Sensitivity Response

submitted

EID3744

In an 80 year old female anaplastic thyroid cancer patient harboring BRAF V600E and TP53 E180K co-mutations, BRAF V600E was associated with response to vemurafenib treatment. Prior to identification o… (full text at CIViC)

PMID 27532222 · Prager et al., 2016 · Open in CIViC

civic

BRAF V600E

Pertuzumab + VemurafenibCombination

Predictive

Supports Sensitivity Response

accepted

EID5961

The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient … (full text at CIViC)

PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC

civic

BRAF V600E

Radiation Therapy + VemurafenibCombination

Predictive

Supports Sensitivity Response

submitted

EID3743

A 51 year old male anaplastic thyroid cancer patient harboring BRAF V600E experienced rapid improvement in response to vemurafenib. The patient was initially treated with paclitaxel and carboplatin bu… (full text at CIViC)

PMID 23406047 · Rosove et al., 2013 · Open in CIViC

civic

Thyroid Gland Carcinoma2
BRAF V600E	Vemurafenib	Predictive	D	Supports Sensitivity Response	—	submitted	EID3784 In an in vitro study, BRAF V600E expressing cell lines (BCPAP, OCUT1, K1 and SW1736) demonstrated increased sensitivity to vemurafenib treatment, compared to BRAF wild-type expressing cells (FTC133, K… (full text at CIViC) PMID 21185263 · Xing et al., 2011 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	D	Supports Sensitivity Response	—	submitted	EID3785 In an in vitro study, the BCPAP cell line expressing a BRAF V600E mutation was associated with sensitivity to vemurafenib treatment. Sensitivity was determined by assessing cell viability and apoptoti… (full text at CIViC) PMID 26456083 · Byeon et al., 2016 · Open in CIViC	civic

Thyroid Gland Carcinoma2

BRAF V600E

Vemurafenib

Predictive

Supports Sensitivity Response

—

submitted

EID3784

In an in vitro study, BRAF V600E expressing cell lines (BCPAP, OCUT1, K1 and SW1736) demonstrated increased sensitivity to vemurafenib treatment, compared to BRAF wild-type expressing cells (FTC133, K… (full text at CIViC)

PMID 21185263 · Xing et al., 2011 · Open in CIViC

civic

BRAF V600E

Vemurafenib

Predictive

Supports Sensitivity Response

—

submitted

EID3785

In an in vitro study, the BCPAP cell line expressing a BRAF V600E mutation was associated with sensitivity to vemurafenib treatment. Sensitivity was determined by assessing cell viability and apoptoti… (full text at CIViC)

PMID 26456083 · Byeon et al., 2016 · Open in CIViC

civic

Thyroid Gland Papillary Carcinoma15
BRAF V600E	(diagnostic)	Diagnostic	B	Supports Positive	5	accepted	EID80 Thyroid nodule with BRAF V600E mutation is highly correlated with papillary thyroid cancer. PMID 24570209 · Crescenzi et al., 2014 · Open in CIViC	civic
BRAF V600E	(prognostic)	Prognostic	B	Does Not Support Poor Outcome	5	accepted	EID102 Unlike other studies that suggest a poorer outcome, BRAF mutation in this study was not correlated with poorer prognosis in papillary thyroid cancer. PMID 24354346 · Walczyk et al., 2014 · Open in CIViC	civic
BRAF V600E	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID105 BRAF mutation correlated with poor prognosis in papillary thyroid cancer in both older (>65 yo) and younger (<65 yo) cohorts. PMID 21594703 · Howell et al., 2011 · Open in CIViC	civic
BRAF V600E	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID106 BRAF V600E is correlated with poor prognosis in papillary thyroid cancer in a study of 187 patients with PTC and other thyroid diseases. PMID 24396464 · He et al., 2014 · Open in CIViC	civic
BRAF V600E	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID107 V600E is correlated with disease recurrence in both age cohorts (>65 and <65 yo). PMID 21594703 · Howell et al., 2011 · Open in CIViC	civic
BRAF V600E	(prognostic)	Prognostic	B	Supports Poor Outcome	5	accepted	EID656 In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T (N=35), recurrence-free survival is worse than in patients harboring one of these mutations (N=… (full text at CIViC) PMID 25024077 · Xing et al., 2014 · Open in CIViC	civic
BRAF V600E	(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID2137 In a study of 102 papillary thyroid cancer patients with a 15 year median follow-up time, those with BRAF V600E mutations had reduced overall survival compared to those with wildtype BRAF (P=0.015, lo… (full text at CIViC) PMID 18682506 · Elisei et al., 2008 · Open in CIViC	civic
BRAF V600E	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID2503 In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5% vs.… (full text at CIViC) PMID 21882184 · Kim et al., 2012 · Open in CIViC	civic
BRAF V600E	(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID9170 Clinical study including 219 patients with papillary thyroid cancer (PTC) to determine a correlation between the BRAF V600E mutation and poor oncological outcome. This study found that 107 of the 219 … (full text at CIViC) PMID 16174717 · Xing et al., 2005 · Open in CIViC	civic
BRAF V600E	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID13013 In transgenic mice with thyroid-specific expression of BRAF V600E, Tg-BRAF2 mice developed papillary thyroid carcinoma (PTC) in 14 of 15 animals at 12 weeks and 13 of 14 animals at 22 weeks. These tum… (full text at CIViC) PMID 15899815 · Knauf et al., 2005 · Open in CIViC	civic
BRAF V600E	Dabrafenib	Predictive	B	Supports Sensitivity Response	3	submitted	EID7761 In a phase 2 trial, patients with radioiodine refractory papillary thyroid carcinoma harboring BRAF mutation were treated with dabrafenib alone or combination with trametinib. 94% patients havd BRAF V… (full text at CIViC) Open in CIViC	civic
BRAF V600E	Dabrafenib + TrametinibCombination	Predictive	B	Supports Sensitivity Response	3	submitted	EID7762 In a phase 2 trial, patients with radioiodine refractory papillary thyroid carcinoma harboring BRAF mutation were treated with dabrafenib alone or combination with trametinib. 94% of patients had BRAF… (full text at CIViC) Open in CIViC	civic
BRAF V600E	Dabrafenib + TrametinibCombination	Predictive	B	Supports Sensitivity Response	3	submitted	EID13281 In a single-center retrospective study of 10 patients with BRAF V600E-positive papillary thyroid carcinoma treated with dabrafenib plus trametinib, 5/10 patients (50%; 95% CI 24–76%) achieved an objec… (full text at CIViC) PMID 40844731 · Ando et al., 2025 · Open in CIViC	civic
BRAF V600E	Dasatinib	Predictive	D	Supports Sensitivity Response	—	submitted	EID3775 In an in vitro study, K2, a papillary thyroid carcinoma cell line expressing the BRAFV600E mutation, was associated with sensitivity to dasatinib treatment. Sensitivity was determined by assessing cel… (full text at CIViC) PMID 23729178 · Henderson et al., 2014 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	B	Supports Sensitivity Response	3	accepted	EID1591 Open-label non-randomised phase 2 trial in patients with recurrent or metastatic BRAF V600E mutant papillary thyroid cancer refractory to radioactive iodine. Patients had (cohort 2) or had not (cohort… (full text at CIViC) PMID 27460442 · Brose et al., 2016 · Open in CIViC	civic

Thyroid Gland Papillary Carcinoma15

BRAF V600E

(diagnostic)

Diagnostic

Supports Positive

accepted

EID80

Thyroid nodule with BRAF V600E mutation is highly correlated with papillary thyroid cancer.

PMID 24570209 · Crescenzi et al., 2014 · Open in CIViC

civic

BRAF V600E

(prognostic)

Prognostic

Does Not Support Poor Outcome

accepted

EID102

Unlike other studies that suggest a poorer outcome, BRAF mutation in this study was not correlated with poorer prognosis in papillary thyroid cancer.

PMID 24354346 · Walczyk et al., 2014 · Open in CIViC

civic

BRAF V600E

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID105

BRAF mutation correlated with poor prognosis in papillary thyroid cancer in both older (>65 yo) and younger (<65 yo) cohorts.

PMID 21594703 · Howell et al., 2011 · Open in CIViC

civic

BRAF V600E

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID106

BRAF V600E is correlated with poor prognosis in papillary thyroid cancer in a study of 187 patients with PTC and other thyroid diseases.

PMID 24396464 · He et al., 2014 · Open in CIViC

civic

BRAF V600E

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID107

V600E is correlated with disease recurrence in both age cohorts (>65 and <65 yo).

PMID 21594703 · Howell et al., 2011 · Open in CIViC

civic

BRAF V600E

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID656

In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T (N=35), recurrence-free survival is worse than in patients harboring one of these mutations (N=… (full text at CIViC)

PMID 25024077 · Xing et al., 2014 · Open in CIViC

civic

BRAF V600E

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID2137

In a study of 102 papillary thyroid cancer patients with a 15 year median follow-up time, those with BRAF V600E mutations had reduced overall survival compared to those with wildtype BRAF (P=0.015, lo… (full text at CIViC)

PMID 18682506 · Elisei et al., 2008 · Open in CIViC

civic

BRAF V600E

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID2503

In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5% vs.… (full text at CIViC)

PMID 21882184 · Kim et al., 2012 · Open in CIViC

civic

BRAF V600E

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID9170

Clinical study including 219 patients with papillary thyroid cancer (PTC) to determine a correlation between the BRAF V600E mutation and poor oncological outcome. This study found that 107 of the 219 … (full text at CIViC)

PMID 16174717 · Xing et al., 2005 · Open in CIViC

civic

BRAF V600E

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID13013

In transgenic mice with thyroid-specific expression of BRAF V600E, Tg-BRAF2 mice developed papillary thyroid carcinoma (PTC) in 14 of 15 animals at 12 weeks and 13 of 14 animals at 22 weeks. These tum… (full text at CIViC)

PMID 15899815 · Knauf et al., 2005 · Open in CIViC

civic

BRAF V600E

Dabrafenib

Predictive

Supports Sensitivity Response

submitted

EID7761

In a phase 2 trial, patients with radioiodine refractory papillary thyroid carcinoma harboring BRAF mutation were treated with dabrafenib alone or combination with trametinib. 94% patients havd BRAF V… (full text at CIViC)

Open in CIViC

civic

BRAF V600E

Dabrafenib + TrametinibCombination

Predictive

Supports Sensitivity Response

submitted

EID7762

Open in CIViC

civic

BRAF V600E

Dabrafenib + TrametinibCombination

Predictive

Supports Sensitivity Response

submitted

EID13281

In a single-center retrospective study of 10 patients with BRAF V600E-positive papillary thyroid carcinoma treated with dabrafenib plus trametinib, 5/10 patients (50%; 95% CI 24–76%) achieved an objec… (full text at CIViC)

PMID 40844731 · Ando et al., 2025 · Open in CIViC

civic

BRAF V600E

Dasatinib

Predictive

Supports Sensitivity Response

—

submitted

EID3775

In an in vitro study, K2, a papillary thyroid carcinoma cell line expressing the BRAFV600E mutation, was associated with sensitivity to dasatinib treatment. Sensitivity was determined by assessing cel… (full text at CIViC)

PMID 23729178 · Henderson et al., 2014 · Open in CIViC

civic

BRAF V600E

Vemurafenib

Predictive

Supports Sensitivity Response

accepted

EID1591

Open-label non-randomised phase 2 trial in patients with recurrent or metastatic BRAF V600E mutant papillary thyroid cancer refractory to radioactive iodine. Patients had (cohort 2) or had not (cohort… (full text at CIViC)

PMID 27460442 · Brose et al., 2016 · Open in CIViC

civic

Evidence by cancer (259 items)

Clinical significance (0)